Medicine & Life Sciences
Amyloid
100%
N-methyl-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole
88%
Alzheimer Disease
86%
Hospital Rapid Response Team
77%
Hospitalists
73%
Cyclooxygenase 1
64%
Clinical Deterioration
62%
Patient Readmission
57%
Ultraviolet Rays
51%
Patient Care
48%
Cerebrospinal Fluid
43%
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
36%
Memory
36%
Hospital Mortality
35%
Atrophy
34%
Cohort Studies
33%
Odds Ratio
31%
Intensive Care Units
30%
Apoptosis
30%
Confidence Intervals
29%
Long-Term Care
26%
Temporal Lobe
24%
Control Groups
20%
Population
19%
Length of Stay
18%
Neoplasms
16%
Hospital Medicine
16%
Young Adult
16%
Parietal Lobe
15%
Hospital Units
14%
Patient Transfer
14%
Nursing Homes
12%
Chemoprevention
12%
Cyclooxygenase 2
11%
Health Care Costs
11%
Gyrus Cinguli
10%
Amyloid Plaques
9%
Primary Health Care
9%
Medicine
9%
Randomized Controlled Trials
8%
Animals
8%
Disease Progression
7%
Cerebellar Cortex
7%
Hairless Mouse
7%
Morbidity
7%
9,10-Dimethyl-1,2-benzanthracene
7%
Squamous Cell Neoplasms
6%
Wild Animals
6%
Occipital Lobe
6%
Magnetic Resonance Imaging
6%
Social Sciences
medication
42%
time
17%
confidence
16%
mortality
13%
acute care hospitals
8%
medicine
7%
Group
6%
discharge date
6%
nursing home
6%
patient care
5%
morbidity
5%